The expo is held as scheduled this year, and it will certainly allow China to accelerate the formation of a "dual circulation" growth pattern in which domestic and international economic cycles complement each other. It will leverage opening-up to foster innovation and development, thus providing continuous momentum to power the integration of trade and innovation globally.
As a world-leading, patient-centric, values-based, R&D-driven biopharmaceutical company, Takeda will make every effort to accelerate the introduction of more first-in-class, best-in-class innovative products and transformative therapies into China, improve the availability of drugs to benefit more patients, and contribute to the Healthy China 2030 initiative.
